Gene · 4299
Papers2,225
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,225
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular Heterogeneity of Pediatric AML with Atypical Promyelocytes Accumulation in Children-A Single Center Experience. | Genes (Basel) | 2023 | 36980947 | PubTator, text mining | PubMed |
| Telomere Transcription in MLL-Rearranged Leukemia Cell Lines: Increased Levels of TERRA Associate with Lymphoid Lineage and Are Independent of Telomere Length and Ploidy. | Biomedicines | 2023 | 36979904 | PubTator, text mining | PubMed |
| Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia. | Biomedicines | 2023 | 36979800 | PubTator, text mining | PubMed |
| MAPK Is a Mutual Pathway Targeted by Anxiety-Related miRNAs, and E2F5 Is a Putative Target for Anxiolytic miRNAs. | Biomolecules | 2023 | 36979479 | PubTator, text mining | PubMed |
| Factors influencing Chinese public attitudes toward farm animal welfare. | Front Psychol | 2023 | 36968749 | PubTator, text mining | PubMed |
| ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. | Blood Cancer J | 2023 | 36959186 | PubTator, text mining | PubMed |
| Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients. | Cancer Med | 2023 | 36951610 | PubTator, text mining | PubMed |
| Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target. | Int J Mol Sci | 2023 | 36902091 | PubTator, text mining | PubMed |
| Dominant Gene Expression Profiles Define Adenoid Cystic Carcinoma (ACC) from Different Tissues: Validation of a Gene Signature Classifier for Poor Survival in Salivary Gland ACC. | Cancers (Basel) | 2023 | 36900183 | PubTator, text mining | PubMed |
| Therapy-Acquired Clonal Mutations in Thiopurine Drug-Response Genes Drive Majority of Early Relapses in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. | Diagnostics (Basel) | 2023 | 36900028 | PubTator, text mining | PubMed |
| Temporal evolution and differential patterns of cellular reconstitution after therapy for childhood cancers. | Sci Rep | 2023 | 36899075 | PubTator, text mining | PubMed |
| Macroscopic resting state model predicts theta burst stimulation response: A randomized trial. | PLoS Comput Biol | 2023 | 36877733 | PubTator, text mining | PubMed |
| Chemo-free maintenance therapy in adult T-cell acute lymphoblastic leukemia: A case report and literature review. | Front Pharmacol | 2023 | 36873995 | PubTator, text mining | PubMed |
| Exploratory integrated analysis of circulating exosomal miRNA and tissue mRNA related to long-term physical activity for more than 25 years: a bioinformatics study. | Eur J Appl Physiol | 2023 | 36867245 | PubTator, text mining | PubMed |
KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study. | Haematologica | 2023 | 36861410 | PubTator, text mining | PubMed |
| Classification and genetics of pediatric B-other acute lymphoblastic leukemia by targeted RNA sequencing. | Blood Adv | 2023 | 36848637 | PubTator, text mining | PubMed |
| Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. | Signal Transduct Target Ther | 2023 | 36843114 | PubTator, text mining | PubMed |
| Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. | Pharmaceutics | 2023 | 36839989 | PubTator, text mining | PubMed |
| Roles of RNA Methylations in Cancer Progression, Autophagy, and Anticancer Drug Resistance. | Int J Mol Sci | 2023 | 36835633 | PubTator, text mining | PubMed |
| Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia. | Genes (Basel) | 2023 | 36833191 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4299/papers?page=11